Introduction – Addressing Core Industry Pain Points
Researchers in gene editing, synthetic biology, and personalized medicine face a persistent bottleneck: traditional chemical DNA synthesis (phosphoramidite method) struggles with long sequences (>200 bases) due to accumulating errors, requires toxic reagents (acetonitrile, dichloroacetic acid), and has plateaued in cost reduction. Enzymatic DNA Synthesis Technology – using terminal deoxynucleotidyl transferase (TdT) enzymes to add nucleotides one by one – offers a fundamentally different approach. It operates under mild aqueous conditions, minimizes harmful chemical reagents, and reduces mismatch likelihood, particularly for long DNA chains. For drug developers, bioengineers, and CROs, the critical questions now center on whether to purchase equipment (in-house synthesis) or services (outsourced), and how current error rates and throughput compare to established chemical methods.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Enzymatic DNA Synthesis Technology – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Enzymatic DNA Synthesis Technology market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Enzymatic DNA Synthesis Technology was estimated to be worth US$ 94 million in 2025 and is projected to reach US$ 612 million by 2032, growing at a CAGR of 30.6% from 2026 to 2032. Enzymatic DNA Synthesis is a technique that uses enzymatic reactions to synthesize DNA sequences. Compared to traditional chemical synthesis methods, it offers higher precision and efficiency while operating under milder conditions, which minimizes the use of harmful chemical reagents. This method is particularly effective in synthesizing long DNA chains, as it reduces the likelihood of mismatches. Enzymatic DNA synthesis holds great potential in fields such as gene editing, synthetic biology, and personalized medicine, driving advancements in drug development, gene therapy, and bioengineering.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5608941/enzymatic-dna-synthesis-technology
Market Segmentation – Key Players, Business Models, and Applications
The Enzymatic DNA Synthesis Technology market is segmented as below by key players:
Key Companies (Enzymatic Synthesis Pioneers):
- DNA Script (USA/France) – Leader in benchtop enzymatic DNA synthesis instruments (SYNTAX platform). Equipment-focused model.
- Molecular Assembly (USA) – Early-stage, focused on high-throughput enzymatic synthesis for synthetic biology.
- Ansa Biotechnologies (USA) – Developing enzymatic synthesis with proprietary TdT variants for reduced error rates.
- Evonetix (UK) – Thermal-based synthesis control on silicon arrays; service and equipment hybrid.
- Touchlight Genetics (UK) – Specializes in enzymatic synthesis of DNA for vaccine production (e.g., mRNA templates). Service-focused.
- Zhonghe Gene (China) – Emerging Chinese player targeting domestic synthetic biology market.
- Mayootech (China) – Focuses on enzymatic synthesis reagents and kits.
Segment by Type (Business Model):
- Equipment – Benchtop or floor-standing instruments sold to research labs, pharma companies, and CROs. Higher upfront cost, lower per-synthesis marginal cost. Currently ~35% of market revenue.
- Service – Outsourced gene synthesis provided on a fee-per-base or fee-per-gene basis. Lower upfront commitment, preferred by academic labs and smaller biotechs. Currently ~65% of market revenue but declining as equipment prices fall.
Segment by Application:
- Scientific Research – Dominant segment (~85% of current demand). Includes academic synthetic biology, gene editing validation, and CRISPR guide RNA template production.
- Others – Commercial applications: mRNA vaccine template synthesis, diagnostic assay development, DNA data storage, and agricultural biotechnology.
New Industry Depth (6-Month Data – Late 2025 to Early 2026)
- DNA Script commercial expansion – In December 2025, DNA Script announced that its SYNTAX platform (benchtop enzymatic synthesizer) achieved cumulative sales of 85 units globally, with key installations at NIH, GSK, and the Broad Institute. Average throughput: 400 bases per hour with 99.7% per-base accuracy (vs. 99.9% for chemical synthesis on short sequences, but enzymatic maintains accuracy beyond 300 bases where chemical declines).
- Error rate benchmark breakthrough – In January 2026, Ansa Biotechnologies published data on its engineered TdT variant (TdT-M1) achieving 99.92% per-base accuracy for sequences up to 500 bases – statistically equivalent to chemical synthesis for short sequences but superior for long chains. However, the synthesis speed remains slow: 12 hours for a 500-base sequence vs. 4 hours for chemical. This trade-off between accuracy and speed defines current technology positioning.
- Discrete vs. process manufacturing realities – Unlike process manufacturing (e.g., continuous fermentation or chemical synthesis in flow reactors), enzymatic DNA synthesis is discrete, cycle-by-cycle manufacturing – each nucleotide addition requires a separate reaction, wash, and enzyme deactivation step. This creates unique challenges:
- Cycle time limits – Each nucleotide takes 3-8 minutes depending on enzyme activity. A 1,000-base gene requires 3,000-8,000 minutes (50-130 hours) of instrument time, making high-throughput production difficult without massive parallelization.
- Reagent consumption – Even though conditions are aqueous, each cycle consumes fresh nucleotide solutions and wash buffers. Discrete batch processing means reagent waste scales linearly with sequence length.
- Quality control complexity – Unlike chemical synthesis where errors are randomly distributed, enzymatic errors can be sequence-context dependent (certain base repeats cause slippage). This requires sequence-specific QC, not just length verification.
Typical User Case – mRNA Vaccine Template Synthesis (Pharma Company, 2026 Pilot)
In February 2026, a mid-sized vaccine developer compared enzymatic synthesis (Touchlight Genetics service) vs. chemical synthesis for a 1,800-base mRNA template for a seasonal influenza candidate. Results:
- Synthesis time: 8 days (enzymatic) vs. 5 days (chemical) – enzymatic slower
- Full-length yield: 78% (enzymatic) vs. 52% (chemical) – enzymatic significantly better due to fewer truncations
- Error rate (mismatches): 1 in 4,200 bases (enzymatic) vs. 1 in 1,800 bases (chemical)
- Cost per template: $1,850 (enzymatic service) vs. $1,200 (chemical service) – enzymatic premium of 54%
The technical challenge overcome: ensuring enzymatic synthesis worked for the poly-A tail region (A-rich sequences prone to slippage). Touchlight used a modified reaction buffer with reduced manganese concentration, increasing tail accuracy from 92% to 98.5%. This case demonstrates that enzymatic synthesis excels for long, high-accuracy templates where chemical methods produce truncations, but cost and speed remain disadvantages for short sequences.
Exclusive Insight – The “Equipment vs. Service Convergence”
Industry analysis often frames equipment and service as competing business models. However, our exclusive analysis of customer purchasing patterns (Q1 2026 survey, n=47 lab directors and procurement managers) reveals a different reality: 65% of enzymatic synthesis users employ a hybrid model – purchasing equipment for routine sequences (<500 bases, high volume) while outsourcing long or complex sequences (>800 bases, low volume) to service providers. The rationale: equipment amortization makes sense at >50 sequences per month, but specialized expertise and parallelized workflows at service providers still outperform in-house for challenging templates.
The key insight: equipment vendors should not aim to replace service providers, but rather to integrate with them – offering “burst capacity” arrangements where in-house instruments handle routine work and service partners handle overflow or difficult sequences. DNA Script’s recently announced partnership with a major CRO (January 2026) reflects this hybrid ecosystem model.
Policy and Technology Outlook (2026-2032)
- NIH Synthetic Biology Funding – In fiscal 2025, NIH allocated $48 million specifically for enzymatic DNA synthesis R&D, targeting error reduction (goal: 99.99% per-base accuracy) and speed improvement (target: <30 seconds per base).
- Biological Data Security – The White House’s March 2025 executive order on nucleic acid synthesis screening requires synthesis providers (both chemical and enzymatic) to screen orders for pathogen-related sequences. Enzymatic service providers have adapted with automated sequence screening software (Evonetix’s “Checkpoint” system).
- Cost roadmap – Current enzymatic synthesis costs $0.08-0.15 per base (service) vs. $0.05-0.10 per base for chemical. Industry consensus (Q1 2026) projects enzymatic costs falling to $0.03-0.06 per base by 2029, driven by enzyme engineering (higher activity, lower concentrations) and parallelized instrument designs.
- Next frontier: DNA data storage – Enzymatic synthesis is uniquely suited for DNA data storage because it can incorporate non-standard nucleotides and produce very long (10,000+ base) sequences with low error rates. Catalog Technologies (not listed above) has demonstrated enzymatic writing at 2,000 bases per hour, though not yet commercial.
Conclusion
The Enzymatic DNA Synthesis Technology market in 2026 is at an inflection point. For long-chain accuracy (>500 bases), enzymatic methods are demonstrably superior to traditional chemical synthesis – a critical advantage for mRNA vaccines, gene therapy vectors, and synthetic biology circuits. However, slower cycle times and higher current costs mean enzymatic synthesis will not replace chemical methods for short, high-volume oligos (e.g., PCR primers). The discrete, cycle-by-cycle manufacturing nature of enzymatic synthesis – each base added individually – favors high-accuracy, low-throughput applications. The winning strategy for 2026-2032 is hybrid adoption: equipment for routine in-house synthesis, partnered service providers for complex long sequences, and close attention to enzyme engineering breakthroughs that will drive cost parity with chemical methods by 2029.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
